BSD Medical's MicroThermX at RSNA - Analyst Blog
Cancer treatment systems maker BSD Medical Corp . ( BSDM ) reported that its MicroThermX Microwave Ablation System ("MicroThermX") was showcased at the recently held Radiology Society of North America ("RSNA") annual meet in Chicago.
The ground-breaking device was promoted as part of a technical exhibition at the RSNA, the largest annual radiology meet on the planet with roughly 58,044 people from over 100 nations attending the event.
BSD Medical leveraged the RSNA meet to exhibit its innovative MicroThermX technology to more radiation oncologists than at any other event. The company's senior sales and marketing managers held strategic meetings with leading U.S. and international distributors.
The MicroThermX system hit the U.S. and European markets in December 2010 and January 2011, respectively. It is a transportable, cutting-edge proprietary product, which includes a microwave generator, single-use antennas and a temperature monitoring mechanism. The device is capable of generating significant levels of power with one generator. Its usage helps approach larger and more uniform areas of ablation during a procedure.
MicroThermX leverages BSD Medical's proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. As such, it can be used by both surgeons and interventional radiologists.
BSD Medical competes with established players like Boston Scientific ( BSX ) and Angiodynamics ( ANGO ) in the thermal ablation market. The global market for soft tissue ablation has been estimated to exceed $2.3 billion, offering a lucrative opportunity for BSD Medical.
ANGIODYNAMICS ( ANGO ): Free Stock Analysis Report
BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report
Zacks Investment Research